Formulation: 25 mM Tris-HCl, pH 8.0, with 69 mM sodium chloride, 1.35 mM potassium chloride, 0.025% Tween 20, 125 mM imidazole, 50% glycerol, and 3 mM DTT
Purity: ≥80% as determined by SDS-PAGE
Shelf life (days): 180
Notes: FMS-like tyrosine kinase 3 (FLT3), also known as CD135, is a transmembrane cytokine receptor and member of the class III receptor tyrosine kinase family.{60916} It is composed of five extracellular immunoglobulin-like (Ig-like) domains, a transmembrane domain, an intracellular juxtamembrane domain, and two intracellular kinase domains. FLT3 is expressed in immature myeloid, lymphoid, and dendritic progenitor cells. Upon binding of FLT3 ligand, FLT3 forms a homodimer and the kinase domains are trans-phosphorylated, leading to activation of the RAS/MEK/ERK, PI3K, and STAT5A signaling pathways in a cell type-dependent manner.{60916,60917} It is involved in the growth, survival, and differentiation of hematopoietic cells. FLT3 is considered a protooncogene, and activating mutations in it are associated with shorter disease-free survival in patients with hematologic malignancies.{60916,60918} A mutation in FLT3 that results in an internal tandem duplication (ITD) of the juxtamembrane domain in FLT3 is found in approximately 20% of patients with acute myeloid leukemia (AML) and is associated with leukocytosis and poor prognosis.{60918,60919} Formulations containing inhibitors of FLT3 have been used in the treatment of AML but are associated with chemoresistance.{60917} Cayman’s FLT3/CD135 Intracellular Domain (human, recombinant) protein can be used for enzyme activity assays.
English
Deutsch
